Jumonji inhibitors against Ewing’s Sarcoma

It is common that by the time Ewing´s Sarcoma is diagnosed, primarily in teens and young adults it has often spread to other parts of the body, making the treatment more difficult.  Marybeth Sechler, a graduate student in the lab of University of Colorado, Cancer Center investigator Paul Jedlicka, MD, Ph.D. published in the journal Oncogene that they identified a protein that may be essential to this spread when researchers knocked down the protein KDM3A in Ewing’s Sarcoma tumor cells, from a family known as Jumonji proteins, they also inhibited cancer’s metastatic ability. The lab’s next steps are to evaluate the use of Jumonji inhibitors against Ewing’s Sarcoma, researchers suggest that these new targets may provide more easily treatment alternatives.

References and Additional links: